wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q38829545-2023AAEE-3631-4B03-BB06-661F94C5ED43
Q38829545-2023AAEE-3631-4B03-BB06-661F94C5ED43
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38829545-2023AAEE-3631-4B03-BB06-661F94C5ED43
Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.
P2860
Q38829545-2023AAEE-3631-4B03-BB06-661F94C5ED43
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38829545-2023AAEE-3631-4B03-BB06-661F94C5ED43
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0ad4ad981232414efde32414ecc8e86c03629508
P2860
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.